KRRO · Korro Bio, Inc.

Track KRRO — free

$10.53 -0.06 (-0.52%)

Russell 2000 member Rebalance outlook locked

Market Cap

$155.80M

14.73M

Volume · Oct 9 38.88K Avg daily vol (3M) 149.11K

Up next

Next earnings call

Nov 9, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$2.38M

Trailing 12 months

Net income (TTM)

−$106.64M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

-4,625.5%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-43.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+87.6%

Year over year · more shares

Price change (1Y)

-76.9%

Trailing year

Short interest

10.5%

Latest settlement · 11.9 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −10%

below

Price vs 50-day avg −11%

below

RSI (14) 46

neutral

MACD trend Positive

52-week position 12%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −19%

trailing

6-month return −26%

trailing

YTD return +32%

this year

Relative strength −35%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $12 › 200d $12 — 50d above 200d

Institutional flow Accumulating

5 of 107 funds reported for Sep 30 · net +293 sh shares · +1 new

Insider flow Distributing

Net -$62.9K over 90 days · 100% sells

Short interest Rising

10.54% of float · ▲ +4.6% MoM · 11.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

107 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Weak

Revenue growth +181%

Y/Y

EPS growth −33%

Y/Y

Free cash flow $-79.1M

Quant / Vol

risk profile

Very High

Volatility 117%

annualized · 1-yr

Max drawdown −90%

past year

ATR 8.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Nov 6, 2023

Cash, cash equivalents and investments · post-transaction $170M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−10% Bearish

Price vs 50-day avg

−11% Bearish

RSI (14)

46 Neutral

MACD trend

Positive Bullish

52-week position

12% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $12 › 200d $12 — 50d above 200d

Institutional flow Accumulating

5 of 107 funds reported for Sep 30 · net +293 sh shares · +1 new

Insider flow Distributing

Net -$62.9K over 90 days · 100% sells

Short interest Rising

10.54% of float · ▲ +4.6% MoM · 11.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

107 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $11 · 12% Range high $51

vs 200-day avg -10% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
KRRO Korro Bio, Inc. this stock	$155.80M	+32.1%	+181.5%	—	10.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$127.55B	+11.0%	+46.2%	29.3	1.9%
MRNA Moderna, Inc.	$78.65B	+568.0%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.14B	-4.2%	+20.8%	18.3	2.5%
CSLLY Csl Ltd	$60.24B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

107

% held: 98.8%
Reported: 5 of 107
Top holder: Lynx1 Capital Management…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

1.6M

Days to cover: 11.9d
Change: +68.3K sh

View

Short Volume

Short vol %

74%

As of: Oct 8, 2026

Short Total

View

Fails to Deliver

FTD shares

911

Value: $12.6K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

34.3%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$62.9K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$6.4M

Net income (FY): $-117.3M
EPS diluted: $-12.48

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 5, 2026
This year: 14

View

Proposed Sales

Value

$69

Shares: 5
Filed: Sep 11, 2026

View

Exempt Offerings

Offering

$42.3M

Filed: Jul 27, 2020

View

Earnings & Events

Webcasts

Last webcast

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
KRRO	+9.0%	-19.0%	-26.5%	+6.8%	+32.1%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	+7.7%	-21.1%	-35.5%	+5.3%	+18.6%

Key facts CIK 1703647 CUSIP 500946108 13F (30d) 5 filings 5 filers Visit website Investor relations

KRRO · Korro Bio, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance